Table 1 Baseline characteristics (N = 74)
Characteristics | Overall | anti-PD-1/TA alone (N = 32) | anti-PD-1/TA + SBRT (N = 42) | P |
|---|---|---|---|---|
No. of patients (%) | ||||
Age, median (range) | 53 (18–83) | 53 (18–83) | 53 (24–75) | 0.571 |
Sex | 0.732 | |||
Male | 54 (73.0) | 24 (75.0) | 30 (71.4) | |
Female | 20 (27.0) | 8 (25.0) | 12 (28.6) | |
Histology | 0.755 | |||
Clear cell | 50 (67.6) | 21 (65.6) | 29 (69.0) | |
Non-clear cell | 24 (32.4) | 11 (34.4) | 13 (31.0) | |
ECOG | 0.253 | |||
0–1 | 38 (51.4) | 14 (43.8) | 24 (57.1) | |
>1 | 36 (48.6) | 18 (56.3) | 18 (42.9) | |
IMDC risk group | 0.461 | |||
Favorable | 16 (21.6) | 5 (15.6) | 11 (26.2) | |
Intermediate | 43 (58.1) | 21 (65.6) | 22 (52.4) | |
Poor | 15 (20.3) | 6 (18.8) | 9 (21.4) | |
Brain metastasis | 2 (2.7) | 1 (3.1) | 1 (2.4) | 1.000 |
Bone metastasis | 18 (24.3) | 4 (12.5) | 14 (33.3) | 0.039 |
Liver metastasis | 9 (12.2) | 6 (18.8) | 3 (7.1) | 0.248 |
Synchronous metastasis | 34 (45.9) | 14 (43.8) | 20 (47.6) | 0.741 |
Oligometastasis | 17 (23.0) | 5 (15.6) | 12 (28.6) | 0.190 |
Nephrectomy | 63 (85.1) | 27 (84.4) | 36 (85.7) | 1.000 |
No. of prior therapies | 1.000 | |||
1 | 63 (85.1) | 27 (84.4) | 36 (85.7) | |
>1 | 11 (14.9) | 5 (15.6) | 6 (14.3) | |